We encourage you to read the privacy policy of every website you visit.AstraZeneca's work environment is dynamic and fosters innovation. AstraZeneca provides this link as a service to website visitors.
Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. It also has a site in New Jersey. As part of the AstraZeneca Group, we will continue the ongoing commitment to progress developments and innovation in respiratory science.Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Pearl Therapeutics is now an asset within AstraZeneca, developing inhaled combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Each location conducts similar activities, said Martin. About Pearl Therapeutics, Inc. Pearl is developing a portfolio of meaningfully differentiated products to treat respiratory diseases including COPD and asthma. “We’re able to attract and retain great employees, which is the foundation of Pearl’s success.”“The company expects continued hiring over the next year to support its research and development programs,” she added.The company currently has about 100 employees developing inhaled combination therapies to treat such respiratory diseases as chronic obstructive pulmonary disease and asthma, using metered dose inhalers. Pipeline Publications Cambridge Gothenburg Gaithersburg Our therapy areas. Leveraging its proprietary particle technology, as well as formulation and product development experience, Pearl is rapidly advancing a pipeline of products that offer patients and healthcare professionals therapies that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics. Upon completion of the merger, AstraZeneca acquired 100% of Pearl’s shares. All therapy areas Oncology Cardiovascular, Renal and Metabolism Respiratory & Immunology Other disease areas All medicines Our company. Pearl Huang is a venture partner at Flagship Pioneering and chief executive officer and director of Cygnal Therapeutics.She is also on the board of KSQ Therapeutics.. Before joining Flagship, Pearl most recently served as senior vice president and global head of therapeutic modalities at Roche, where she oversaw the discovery of biologic, small molecule, and nucleic acid-based therapies. " Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma.